Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $28.6 million.

  • Amphastar Pharmaceuticals' Net Cash Flow rose 101785.16% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 13058.81%. This contributed to the annual value of $7.5 million for FY2024, which is 16513.02% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Net Cash Flow stood at $28.6 million, which was up 101785.16% from $4.8 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Net Cash Flow's 5-year high stood at $119.8 million during Q3 2023, with a 5-year trough of -$126.3 million in Q4 2023.
  • In the last 5 years, Amphastar Pharmaceuticals' Net Cash Flow had a median value of $4.8 million in 2025 and averaged $6.5 million.
  • Within the past 5 years, the most significant YoY rise in Amphastar Pharmaceuticals' Net Cash Flow was 145914.45% (2023), while the steepest drop was 1073845.49% (2023).
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Cash Flow (Quarter) stood at $19.8 million in 2021, then tumbled by 105.89% to -$1.2 million in 2022, then tumbled by 10738.45% to -$126.3 million in 2023, then skyrocketed by 67.93% to -$40.5 million in 2024, then soared by 170.67% to $28.6 million in 2025.
  • Its Net Cash Flow was $28.6 million in Q3 2025, compared to $4.8 million in Q2 2025 and $31.1 million in Q1 2025.